SRPT – HedgeChatter

Top 5 Biotech Stocks That The Smart Money Doesn't Like – Benzinga

Preface: The biotech stocks considered for this review were confined to those over $10 per share that traded at least 500K shares a day based on a 90-day average.For the longest time it seemed that for every new high the S&P 500 hit, biotech stocks, as measured by the iShares Nasdaq Biotechnology Index (NASDAQ: IBB), hit two new highs.Biotechnology […]

February 17, 2015 ByChristian Tharp CMT benzinga, biotechnology, GILD, health, industry, MYGN, nasdaq, OPK, pharmaceuticals, SRPT, therapeutics Comments Off read more

Sarepta Therapeutics’s (SRPT) CEO Chris Garabedian Presents at Deutsche Bank Healthcare Conference (Transcript)

[at Seeking Alpha] – Chris Garabedian Yes, thanks Robyn. The guidance we received the couple of weeks ago and we had a conference call on was really what we are waiting for. It had been a long year. We had many interactions … moreView todays social media effects on SRPTView the latest stocks trending across Twitter. Click to view dashboardSee […]

May 10, 2014 Bystocknews SRPT, stock Comments Off read more

Sarepta to hold a conference call

moreView todays social media effects on SRPTView the latest stocks trending across Twitter. Click to view dashboardSee who Sarepta is hiring next, click here to view […]

May 9, 2014 Bystocknews SRPT, stock Comments Off read more

Sarepta Therapeutics’ (SRPT) CEO Chris Garabedian on Q1 2014 Results – Earnings Call Transcript

[at Seeking Alpha] – Chris Garabedian Thank you, Jim. Good morning everyone and thank you for joining us today for our financial and corporate update for the first quarter of 2014. It is proving to be a very exciting year … moreView todays social media effects on SRPTView the latest stocks trending across Twitter. Click to view dashboardSee who Sarepta […]